• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Marina Biotech reduces board size, seeks funding

Marina Biotech reduces board size, seeks funding

August 22, 2012
CenterWatch Staff

Marina Biotech, a nucleic acid-based drug discovery and development company, continues to seek adequate funding to implement its business plan.

To align the size of its board of directors with its strategic objectives, the company has reduced the size of its board to three members. The board will now consist of J. Michael French, Stefan Loren, Ph.D., and Joseph W. Ramelli. The board unanimously appointed Loren and Ramelli to the board Aug. 20 to fill the vacancies created by the resignations of Peter D. Parker and Gregory Sessler. Following the appointments, on Aug. 21 James M. Karis, R. John Fletcher and Michael D. Taylor, Ph.D., also resigned from the board. French will become chairman of the board.

To generate revenue, reduce debt and conserve cash, Marina Biotech has:

  • Entered into a licensing agreement with Novartis Institutes for Biomedical Research for Marina's Conformationally Restricted Nucleotide (CRN) technology for the development of both single- and double-stranded oligonucleotide therapeutics. The Company received $1 million in upfront fees for the non-exclusive license.
  • Negotiated an amendment and extension on the company's secured loan such that if the company effects a merger or consolidation that results in a change-of-control before Dec. 31, 2012, any unpaid principal and interest will convert to common stock, thus eliminating the company's cash obligation to its secured lender.
  • Negotiated with certain unsecured creditors to reduce its cash obligations through the issuance of shares of common stock.

"We continue to work hard to realize the true value of the nucleic acid platform we've created over the past years," said French, president and CEO.

Marina continues to identify strategic opportunities and seek additional funding. If sufficient additional funds are not received in the near term, the company said it may need to further reduce or cease operations completely.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing